Here's an interview that I did recently with Paul Howard of the Manhattan Institute on the results of that immunotherapy leukemia trial (and on some broader topics around the current state of drug discovery). Anyone who would like to pitch a blockbuster syndicated radio show with me on structure-activity relationships and preclinical drug development, have your people call my people.
In a new report released, "In the Wake of Wyeth v. Levine: Making the Case for FDA Preemption and Administrative Compensation," Manhattan Institute scholars Paul Howard and James Copland respond to the recent Supreme Court Case ruli... Read Post
Scientists at Cold Spring Harbor Laboratory (CSHL) and five other institutions have used an unconventional approach to cancer drug discovery to identify a new potential treatment for acute myeloid leukemia (AML). As reported in Natu... Read Post